You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

  • Technology appraisal guidance
  • Reference number: TA1109
  • Published:  12 November 2025
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

31253-Darolutamide-Androgen-Deprivation-Therapy-for-Prostate-Cancer-V1.0-APR2024-NON-CONF.pdf (nihr.ac.uk)

This page was last updated: 12 November 2025

Back to top